Outcome of the Board meeting held on 07.11.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical's board met on November 7, 2025 and approved unaudited results for Q2 and H1 FY26 (ended September 30, 2025). Revenue rose modestly to Rs 14.30 crore in Q2 from Rs 14.01 crore a year ago, and H1 revenue grew to Rs 29.21 crore from Rs 26.63 crore. However, losses deepened sharply — Q2 pre-tax loss widened to Rs 6.44 crore versus Rs 2.77 crore last year, and H1 net loss stood at Rs 11.06 crore. The balance sheet remains weak with negative shareholder equity of around Rs 36.68 crore, meaning accumulated losses have wiped out share capital. The board also appointed Mr. Prasad Reddy Battinapatla, a Chartered Accountant with 15 years of finance experience, as the new CFO effective the same day, and cleared a postal ballot notice with a scrutinizer appointed for the e-voting process.
Revenue is inching up but losses are widening and the company is sitting on deeply negative equity, which is a red flag for shareholders. The new CFO appointment may help tighten financial controls, but until losses narrow, the stock is likely to remain under pressure.